News & Updates

The tyrosine kinase inhibitor imatinib may reduce mortality in patients hospitalized with severe COVID-19, according to follow-up results of the CounterCOVID study presented at ATS 2022.

Antibiotic use appears to be harmful for older adults, with a recent study showing that regardless of class, the drugs raise the risk of developing inflammatory bowel disease (IBD).

Men receiving testosterone therapy (TT) who develop polycythemia are at greater risk for major adverse cardiovascular events (MACE) and venous thromboembolism (VTE) in the first year of therapy, according to a recent study.

In outpatients with an early diagnosis of COVID-19 at high risk for serious illness, treatment with the antiparasitic ivermectin did not reduce the incidence of hospital admission due to disease progression or of prolonged emergency department observation, findings from the TOGETHER trial suggest.

Following discontinuation of nucleot(s)ide analogue therapy, only about one-third of patients with HBeAg-negative chronic hepatitis B (CHB) achieve disease remission, with rare HBsAg loss, as reported in a study. The likelihood of HBsAg loss and disease remission is high in the presence of very low HBsAg levels at baseline.

Use of statins results in reduced all-cause mortality in nearly 30,000 veterans with colorectal cancer (CRC), results of a study have shown.

Switching from triple therapy to dual bronchodilation improves symptom control in patients with chronic obstructive pulmonary disease (COPD) in a new analysis of the DACCORD study.